Journal of APPLIED BIOMEDICINE
ISSN 1214-0287 (on-line)
ISSN 1214-021X (printed)

Volume 3 (2005), No 3, p 147-153




Positron emission tomography (PET) in residual post-treatment Hodgkin's disease masses

Gustavo H. Marin, Jorge Dellagiovanna, Pablo Urdampilleta

Address: Gustavo H. Marin, Instituto Central de Medicina, Servicio de Hematologia, Calle 43 no 584 (1900) La Plata, Argentina
gmarin@netverk.com.ar

Received 7th April 2005.
Revised 25th May 2005.
Published online 1st July 2005.

Full text article (pdf)

SUMMARY
Hodgkin's disease (HD) is one of the malignant diseases with good chances for a cure. The prognosis for cure depends on the initial stages and the outcome after initial treatment. Stages I or II at diagnosis, or a complete remission after initial treatment are good indicators for the best prognosis to patients.
A frequent problem faced by clinicians is met at the post-therapy stage because of the difficulty of distinguishing between dead tissue and disease activity in residual masses. Considering that these two situations include therapy options that run from treatment abstention to autologous stem cell transplantation, it is extremely important to distinguish them accurately.
Classical Tomography Scan (CT Scan), Gallium scintigraphy, Magnetic Resonance Imaging (MRI) or Positron Emission Tomography (PET) are used to investigate residual masses. In order to clarify the best way to confirm the post-treatment status of patients affected by HD, we describe in this paper our experience of using PET to solve those problem situations where a CT Scan or MRI were not conclusive and Gallium was negative.

KEY WORDS
PET; Hodgkin; residual


REFERENCES
Canellos GP: Residual mass in lymphoma may not be residual disease. J Clin Oncol 6:931-933, 1988.

De Wit M, Bohuslavizki KH, Buchert R et al.: (18)FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 12:29-37, 2001.

Glimelius I, Molin D, Amini RM et al.: Bulky disease is the most important prognostic factor in Hodgkin lymphoma stage IIB. Eur J Haematol 71:327-333, 2003.

Hill M, Cunningham D, MacVicar D et al.: Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol 11:2273-2278, 1993.

Hoh CK, Glaspy J, Rosen P et al.: Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 38:343-348, 1997.

Israel O, Front D, Lam M et al.: Gallium 67 imaging in monitoring lymphoma response to treatment. Cancer 61:2439-2443, 1988.

Jerusalem G, Beguin Y, Fassotte MF et al.: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429-433, 1999.

Kostakoglu L, Yeh SD, Portlock C et al. Validation of gallium-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. J Nucl Med 33:345-350, 1992.

Nyman R.S., Rehn S.M., Glimelius B.L. et al.: Residual mediastinal masses in Hodgkin disease: prediction of size with MR imaging. Radiology 170:435-440, 1989.

Radford JA, Cowan RA, Flanagan M et al.: The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol 6:940-946, 1988.

Schaefer NG, Hany TF, Taverna C et al.: Non- Hodgkin lymphoma and Hodgkin disease: co registered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology 232:823-829, 2004.

Setoain FJ, Pons F, Herranz R et al.: Ga-67 scintigraphy for the evaluation of recurrences and residual masses in patients with lymphoma. Nucl Med Commun 18:405-411, 1997.

Weihrauch MR, Re D, Scheidhauer K et al.: Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98:2930-2934, 2001.

Zinzani PL, Magagnoli M, Chierichetti F et al.: The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 10:1181-1184, 1999.
CITED

0

BACK